Schedule 13G - Passive Investments
NASDAQ
CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amendment to their beneficial ownership of Galmed Pharmaceuticals Ltd., reporting a 3.1% stake.
NASDAQ
CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., disclosed a 7.1% beneficial ownership stake in Galmed Pharmaceuticals Ltd. through warrants.
NASDAQ
SCHEDULE 13G/A: Insider Allen Baharaff Discloses 2.6% Stake in Galmed Pharmaceuticals Following Share Split and Corporate Dissolution
Allen Baharaff, a former controlling shareholder of G. Yarom Medical Research Ltd., reported a 2.6% beneficial ownership in Galmed Pharmaceuticals Ltd. as of December 31, 2024, following a reverse share split and the dissolution of G. Yarom Medical Research Ltd.